- Recent IPO Praxis Precision Medicines (PRAX -27.0%) craters on average volume in reaction to the FDA's clinical hold on its Investigational New Drug (IND) application for lead candidate PRAX-114, an extrasynaptic-preferring GABAa receptor positive allosteric modulator, for the potential treatment of major depressive disorder (MDD) and perimenopausal depression.
- The company says the agency has not explained the reason for the hold, which prohibits the start of its planned Phase 2/3 clinical trial in MDD, only saying that its comments have yet to be finalized.
- https://seekingalpha.com/news/3634401-praxis-precision-medicine-plummets-27-on-clinical-hold-on-lead-drug
Search This Blog
Tuesday, November 10, 2020
Praxis Precision Medicine plummets on clinical hold on lead drug
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.